CJC-1295 + Ipamorelin 20mg (No DAC) – Research Peptide Blend
Product Overview
CJC-1295 + Ipamorelin is a dual-peptide formulation intended for controlled laboratory research involving growth hormone-related signaling pathways.
The formulation combines a growth hormone-releasing hormone (GHRH) analogue without Drug Affinity Complex (DAC) and a growth hormone secretagogue receptor (GHSR) agonist.
Peptide Composition
Each vial contains:
- CJC-1295 (No DAC) – 10 mg: A synthetic GHRH analogue investigated for its interaction with growth hormone-releasing hormone receptors and its role in growth hormone signaling.
- Ipamorelin – 10 mg: A synthetic peptide investigated for its agonist activity at the growth hormone secretagogue receptor (GHSR) and its effects on growth hormone-related signaling pathways.
Total Peptide Content: 20 mg per vial
Research Applications
Potential areas of laboratory investigation include:
- Growth hormone-releasing hormone receptor signaling
- Growth hormone secretagogue receptor activity
- Peptide receptor interactions
- Growth hormone secretion pathways
- Molecular characterization of dual-peptide formulations
- Peptide stability and biochemical analysis
Product Specifications
- Product Name: CJC-1295 + Ipamorelin (No DAC)
- CJC-1295 (No DAC): 10 mg
- Ipamorelin: 10 mg
- Total Content: 20 mg
- Physical Form: Lyophilized powder
- Reported Purity: 99.76% (pending batch-specific COA verification)
- Storage: 2–8°C (subject to manufacturer confirmation)
- Intended Use: Laboratory research only
Quality & Testing
Batch-specific laboratory analysis should verify the identity, quantity, and purity of each peptide component.
A Certificate of Analysis (COA) should document the applicable analytical results and testing methods.
The reported purity of 99.76% should be verified against the corresponding batch documentation.
Research Use Disclaimer
For laboratory research use only.
Not for human or veterinary consumption, injection, or therapeutic applications.
This research formulation is not approved for clinical use.
Avis
Il n’y pas encore d’avis.